Adocia Completes Phase 3 Trial of BioChaperone®Lispro with Positive Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Source: Yahoo Finance
- Successful Phase 3 Trial: Adocia's BioChaperone®Lispro, in collaboration with Tonghua Dongbao, achieved positive results in both type 1 and type 2 diabetes patients, demonstrating non-inferior HbA1c reduction compared to Humalog®, marking a significant breakthrough in diabetes treatment.
- Patent Application for New Technology: The company has filed a patent for its AdoXLongTM platform, which enables monthly peptide injections, with initial positive in vitro and in vivo results indicating broad application potential in obesity and diabetes treatment.
- Strong Financial Position: As of December 31, 2025, Adocia reported a cash position of €17.2 million, bolstered by a €10 million fundraising completed in December 2025, ensuring funding needs until early 2027 and reflecting solid financial health.
- Board Restructuring: In compliance with statutory age limits, Gérard Soula will step down as Chairman of the Board, with Stéphane Boissel appointed as the new Chairman and Jacky Vonderscher co-opted as a Director, indicating a significant governance transition for the company.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
